Information Provided By: 
Fly News Breaks for June 26, 2019
EIGR
Jun 26, 2019 | 05:42 EDT
Citi analyst Yigal Nochomovitz initiated Eiger BioPharmaceuticals with a Buy rating and $22 price target, noting that he assumes 60% odds of success for lonafarnib and 50% odds of success for pegylated interferon, both of which the company is developing to treat hepatitis D. Eiger is also developing lonafarnib for progeria, a fatal rare disease marked by premature aging, noted Nochomovitz, who assumes a 90% chance of success in that indication.
News For EIGR From the Last 2 Days
There are no results for your query EIGR
